Similar to FTO inhibitors, METTL3 inhibitors have been produced and studied in recent years, and they will be a potent potential target to treat patients with hematological malignancies in the future, especially AML and chemoresistant CML. This evidence concerns the gene METTL3 and acute myeloid leukemia.